Agenda Topics- Antibody Drug Conjugates (ADCs)
- CAR/CAR-T Cells
- Humanised Single Domain Antibodies for Research and Therapeutic Applications
- Novel Immune Check Point Therapeutics, PD1 and Beyond
- Patented Antibodies and Related Technologies in Europe
- Targeting Ion Channels with Biologics
Sponsorship and Exhibition OpportunitiesExhibition Team, exhibitors@selectbio.com +44 (0) 1206 501654
|
Distinguished FacultyRobert Williams, Chief Drug Development Scientist, Cancer Research UK Mahendra Deonarain, Chief Science & Operating Officer, Antikor Biopharma Ltd Trevor Hallam, Chief Scientific Officer, Sutro Biopharma Inc Roger Beerli, CSO, NBE Therapeutics Martin Pule, Director Chimeric Antigen Receptor (CAR) Programme. Founder & Chief Scientific Officer, UCL Autolus John Castle, Executive Director, Vaccine Research and Translational Medicine, Agenus Switzerland Inc. Stefan Dubel, Full Professor and Director, Technische Universität Braunschweig Franck Perez, Group Leader, Institut Curie Stefan Weigand, Head of Large Molecule Research, F. Hoffmann-La Roche Ltd Patrick Chames, Main Scientist, INSERM Roman Kischel, Principal Scientist, Amgen Research Lioudmila Tchistiakova, Senior Director, Pfizer Inc John Li, Senior Scientist, MedImmune Tristan Vaughan, Vice President, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd
|